UNH · Unitedhealth Group Inc

Track UNH — free

$395.72 -13.66 (-3.34%) At close · Nov 5

S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked

Market Cap

$354.57B

896.02M

Volume · Nov 5 6.88M Avg daily vol (3M) 5.15M

Up next

Next earnings call

Jan 9, 2027 Est · unconfirmed · in 9 wks

Q3 2026 earnings call transcript

call held Oct 13, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 3

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Revenue $112.69B ▼ 0.4% Net income $4.11B ▲ 75.0% Diluted EPS $4.56 ▲ 76.1%

Oct 13

Earnings call

Q3 2026 earnings call

United Health Group reported Q3-2026 revenue of $113 billion, adjusted EPS of $4.69 versus $2.92, and a medical care ratio of 88.4%; updated 2026 adjusted EPS guidance is at least $20.50.

Oct 13

Current report 8-K

Financial results

UnitedHealth Group reported third quarter 2026 revenues of $112.7 billion, earnings from operations of $6.6 billion and adjusted earnings of $4.69 per share, and raised full year 2026 guidance to adjusted earnings of at least $20.50 per share.

Read from the first part of this long document

Sep 8

Current report 8-K

Regulation FD disclosure AI summary on its way

Aug 10

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $112.03B ▲ 0.4% Net income $5.48B ▲ 61.0% Diluted EPS $6.04 ▲ 61.5%

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$449.66B

Trailing 12 months

Net income (TTM)

$15.88B

Trailing 12 months

Revenue growth YoY

-0.4%

Year over year

Operating margin

5.3%

Trailing 12 months

P / E (TTM)

23.3

Trailing earnings · reciprocal yield 4.3%

FCF yield

6.2%

TTM · current market cap

Return on invested capital

13.5%

Trailing 12 months

Net cash

−$45.78B

Latest balance sheet

Dividend yield

2.2%

Trailing 12 months

Shares change YoY

-0.7%

Year over year · fewer shares

Price change (1Y)

+23.7%

Trailing year

Short interest

1.6%

Latest settlement · 2.1 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

▲6.8% $100.81B $5.54B '24 Q4* ▲9.8% $109.58B $6.29B '25 Q1 ▲12.9% $111.62B $3.41B '25 Q2 ▲12.2% $113.16B $2.35B '25 Q3 ▲12.3% $113.22B $10.00M '25 Q4* ▲2% $111.72B $6.28B '26 Q1 ▲0.4% $112.03B $5.48B '26 Q2 LATEST ▼0.4% $112.69B $4.11B '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Research

our published analysis of this company

Mentioned in fund letters

Hilton Capital Management, LLC May 2, 2025

Navigating a Shifting Landscape: Defensive Repositioning and Selective Conviction in DIVYS 1Q25

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 16.6 · calm Equity put/call 0.44

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +9%

above

Price vs 50-day avg +1%

above

RSI (14) 47

neutral

MACD trend Negative

52-week position 77%

mid-range

Momentum

relative strength

Strong

1-month return +7%

trailing

6-month return 0%

trailing

YTD return +20%

this year

Relative strength +1%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $391 › 200d $364 — 50d above 200d

Institutional flow Accumulating

1,818 of 3,429 funds reported for Sep 30 · net +2.0M sh shares · +73 new

Insider flow Distributing

Net -$455.9K over 90 days · 100% sells

Short interest Falling

1.56% of shares out · ▼ -12.2% MoM · 2.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

3,429 holders — mid 3-yr range

Squeeze score 48

elevated · 0–100

Fundamentals

Fair

Revenue growth +12%

Y/Y

EPS growth −15%

Y/Y

Free cash flow $16.1B

Valuation P/E 22.6

in line

Balance sheet $54.0B

net debt

Quant / Vol

risk profile

Moderate

Volatility 35%

annualized · 1-yr

Max drawdown −27%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 5 of last 7

Latest guidance · from the 8-K filed Oct 13, 2026

full year 2026

Adjusted net earnings at least $20.50

Full Year 2026

Earnings at least $19.50

prior FY $13.23 midpoint +47.4% Y/Y

Previous outlook earlier release · from the Earnings Call filed Jul 16, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted earnings per share · full year 2026 $19.50 – $20.00

Operating earnings for UnitedHealthcare · full year 2026 at least $12B

Operating earnings for OptumHealth · full year 2026 at least $2.2B

Medical care ratio · full year 2026 88.1%

Share repurchases · full year 2026 at least $5B

Medicare margin · full year 2026 at least 3%

UnitedHealthcare operating earnings · full year 2026 at least $12B

OptumHealth operating earnings · full year 2026 at least $2.2B

Guided vs delivered · last 7 settled

Net earnings Full Year 2025

guided at least $14.90

guided at least $14.90 $13.23 Miss −11.2%

Net earnings outlook full year 2024

guided $15.95 – $16.40

guided $15.95 – $16.40 $15.51 Miss −4.1%

Net earnings per share full year 2023

guided $23.60 – $23.75

guided $23.60 – $23.75 $23.86 Beat +0.8%

Revenues 2023

guided $357B – $360B

guided $357B – $360B $371.62B Beat +3.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+9% Bullish

Price vs 50-day avg

+1% Bullish

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

77% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $391 › 200d $364 — 50d above 200d

Institutional flow Accumulating

1,818 of 3,429 funds reported for Sep 30 · net +2.0M sh shares · +73 new

Insider flow Distributing

Net -$455.9K over 90 days · 100% sells

Short interest Falling

1.56% of shares out · ▼ -12.2% MoM · 2.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

3,429 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $259 Now $396 · 77% Range high $436

vs 200-day avg +9% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted earnings from operations non-GAAP	$23.21B	Nine Months Ended September 30, 2026	—
Adjusted earnings per share attributable to UnitedHealth Group common shareholders non-GAAP	$18.3	Nine Months Ended September 30, 2026	—
Adjusted net earnings per share non-GAAP	$4.69	Q3 2026	—
Adjusted operating margin non-GAAP	5.6%	Three Months Ended September 30, 2026	—
Adjusted operating margin (UnitedHealth Group Consolidated) non-GAAP	6.9%	Nine Months Ended September 30, 2026	—
Adjusted revenues non-GAAP	$336.39B	Nine Months Ended September 30, 2026	—
Adjusted scripts non-GAAP	393M	Q3 2026	—
Cash flows from operations / net income ratio	1.2	Q3 2026	—
Commercial Fee-based (People Served)	22.18M	September 30, 2026	—
Commercial Risk-based (People Served)	7.58M	September 30, 2026	—
Days claims payable	47	Q3 2026	—
Days sales outstanding	16.9	Q3 2026	—
Debt-to-capital ratio	41.7%	as of September 30, 2026	—
Medicaid	6.7M	September 30, 2026	—
Medical cost ratio	88.4%	Q3 2026	—
Medicare Advantage	7.61M	September 30, 2026	—
Medicare Part D stand-alone	2.69M	September 30, 2026	—
Medicare Supplement (Standardized)	4.25M	September 30, 2026	—
Net medical reserve development	610M	Q3 2026	—
Operating cost ratio	12.8%	Q3 2026	—
Operating margin (Optum Health)	3.2%	Q3 2026	—
Operating margin (UnitedHealthcare)	3.3%	Q3 2026	—
Optum Health Consumers Served	92M	September 30, 2026	—
Optum patients and consumers served	120M	Q3 2026	—
Optum Rx adjusted scripts	393M	third quarter 2026	—

South American businesses held for sale	1.14M	September 30, 2026	—
Total Commercial	29.76M	September 30, 2026	—
Total Community and Senior	18.55M	September 30, 2026	—
Total UnitedHealthcare - Medical	48.3M	September 30, 2026	—
UnitedHealthcare Community & State people served change	85,000	Q3 2026	—
UnitedHealthcare consumers served	48.3M	Q3 2026	—
UnitedHealthcare Employer & Individual people served change	165,000	Q3 2026	—
UnitedHealthcare Medicare & Retirement senior membership change since year-end 2025	935,000	Q3 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
UNH Unitedhealth Group Inc this stock	$354.57B	+19.9%	+11.8%	22.6	1.6%
CVS CVS HEALTH Corp	$102.31B	+2.5%	+7.8%	9.3	1.3%
ELV Elevance Health, Inc.	$93.81B	+23.2%	+12.5%	18.4	2.4%
CI Cigna Group	$80.70B	+9.5%	+11.2%	13.5	2.6%
HUM Humana Inc	$50.12B	+60.8%	+10.1%	39.4	3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

3,411

% held: 95.8%
Reported: 1,818 of 3,429
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,696

View

Short & Settlement

Short Interest Falling

Shares short

14.0M

Days to cover: 2.1d
Change: -1.9M sh

View

Short Volume

Short vol %

32%

As of: Nov 5, 2026

Short Total

View

Fails to Deliver

FTD shares

162

Value: $60.7K
As of: Sep 30, 2026

View

Off-Exchange

Off-exchange %

46.9%

Week of: Sep 28, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$455.9K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Maria Elvira Salazar

Amount: $1.0K–$15.0K
Traded: Sep 24, 2026

View

Financials

Revenue (FY)

$447.6B

Net income (FY): $12.1B
EPS diluted: $13.23

View

Buybacks

Authorized

shares 35.0M

Remaining: shares 21.0M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 3, 2026
This year: 19

View

Proposed Sales

Value

$455.9K

Shares: 1.2K
Filed: Aug 21, 2026

View

Earnings & Events

Webcasts

Last webcast

Oct 13, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
UNH	-3.7%	+6.7%	+0.5%	-2.8%	+19.9%
SPY	-4.7%	-5.3%	-0.8%	-3.0%	+7.5%
vs SPY	+1.0%	+12.0%	+1.3%	+0.3%	+12.4%

Capital returns

Latest dividend

$2.32 / share · ex Sep 14, 2026

Declared · upcoming

$2.32 / share · ex Dec 7, 2026

Raised 5%

Paid (TTM)

$9.06 / share · 4 payouts

Dividend yield (TTM, derived)

2.29%

Full dividend history

Buyback program · as of Dec 31, 2025

Authorized

shares 35.00M

Spent (derived)

shares 14.00M

Remaining

shares 21.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 731766 CUSIP 91324P102 13F (30d) 1747 filings 1679 filers Visit website Investor relations

UNH · Unitedhealth Group Inc

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Research

Mentioned in fund letters

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns